{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"# with reductions > 30% relative to baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"# with reductions > 50% relative to baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"groups":[{"description":"This was a non-randomized, open-label, single arm study; all patients in the study received treatment with everolimus.","id":"OG000","title":"Everolimus"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"During the entire study","title":"Overall Reduction in SEGA Tumor Volume.","type":"SECONDARY","unitOfMeasure":"participants"}